glp-1 receptor agonists blindness risk as Treatments for Type 2 Diabetes Glucagon-Like Peptide-1 Receptor Agonists and
Description
These agents can promote vascular function by vasodilation and improve endothelial function by enhancing nitric oxide production [3, 6, 7]
Liu Z, Yang H, Zhi L, et al
Second, oral Wegovy at the higher 25 mg dose has been approved in the US since December 2025
The advent of oral formulations, including semaglutide and ofrutide, has further enhanced patient adherence
This results in a reduction in calorie intake and weight loss
